HK1225638A1 - Modulators of complement factor b - Google Patents

Modulators of complement factor b

Info

Publication number
HK1225638A1
HK1225638A1 HK16114054A HK16114054A HK1225638A1 HK 1225638 A1 HK1225638 A1 HK 1225638A1 HK 16114054 A HK16114054 A HK 16114054A HK 16114054 A HK16114054 A HK 16114054A HK 1225638 A1 HK1225638 A1 HK 1225638A1
Authority
HK
Hong Kong
Prior art keywords
modulators
complement factor
complement
factor
Prior art date
Application number
HK16114054A
Other languages
Chinese (zh)
Inventor
R Grossman Tamar
L Mccaleb Michael
T Watt Andrew
M Freier Susan
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Publication of HK1225638A1 publication Critical patent/HK1225638A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21047—Alternative-complement-pathway C3/C5 convertase (3.4.21.47), i.e. properdin factor B
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Epidemiology (AREA)
  • Amplifiers (AREA)
  • Optical Communication System (AREA)
HK16114054A 2013-09-13 2016-12-09 Modulators of complement factor b HK1225638A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361877624P 2013-09-13 2013-09-13

Publications (1)

Publication Number Publication Date
HK1225638A1 true HK1225638A1 (en) 2017-09-15

Family

ID=52666522

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16114054A HK1225638A1 (en) 2013-09-13 2016-12-09 Modulators of complement factor b

Country Status (33)

Country Link
US (4) US20160222389A1 (en)
EP (2) EP3043827B1 (en)
JP (3) JP6666250B2 (en)
KR (1) KR102381790B1 (en)
CN (2) CN112359042A (en)
AU (2) AU2014318580B2 (en)
BR (1) BR112016004671B1 (en)
CA (1) CA2921842A1 (en)
CL (2) CL2016000606A1 (en)
CR (1) CR20160170A (en)
DK (1) DK3043827T3 (en)
DO (1) DOP2016000063A (en)
EA (1) EA035433B1 (en)
ES (1) ES2745758T3 (en)
HK (1) HK1225638A1 (en)
HR (1) HRP20191600T1 (en)
HU (1) HUE045109T2 (en)
IL (1) IL244095A0 (en)
LT (1) LT3043827T (en)
MA (1) MA38959A1 (en)
MX (2) MX371518B (en)
MY (1) MY181251A (en)
PE (2) PE20160500A1 (en)
PH (1) PH12016500443A1 (en)
PL (1) PL3043827T3 (en)
PT (1) PT3043827T (en)
RS (1) RS59252B1 (en)
RU (1) RU2662967C2 (en)
SG (2) SG11201601445XA (en)
SI (1) SI3043827T1 (en)
UA (1) UA119046C2 (en)
WO (1) WO2015038939A2 (en)
ZA (1) ZA201601236B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2092065B2 (en) 2006-10-18 2019-07-24 Ionis Pharmaceuticals, Inc. Antisense compounds
US10017764B2 (en) 2011-02-08 2018-07-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
AU2014259759B2 (en) 2013-05-01 2020-06-18 Ionis Pharmaceuticals, Inc. Compositions and methods
CA2921842A1 (en) * 2013-09-13 2015-03-19 Ionis Pharmaceuticals, Inc. Modulators of complement factor b
CA3107872A1 (en) * 2013-12-12 2015-06-18 Alnylam Pharmaceuticals, Inc. Complement component irna compositions and methods of use thereof
RU2701645C2 (en) 2014-05-01 2019-09-30 Ионис Фармасьютикалз, Инк. Compositions and methods for modulating complement factor expression b
WO2017135397A1 (en) * 2016-02-05 2017-08-10 協和発酵キリン株式会社 Antisense oligonucleotide for suppressing expression of complement b factor
WO2018005552A1 (en) 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
TW201827596A (en) * 2016-12-23 2018-08-01 日商協和醱酵麒麟有限公司 Nucleic acid inhibiting expression of complement factor B
WO2019027015A1 (en) * 2017-08-02 2019-02-07 協和発酵キリン株式会社 Nucleic acid complex
SG11202002940QA (en) 2017-11-01 2020-04-29 Alnylam Pharmaceuticals Inc Complement component c3 irna compositions and methods of use thereof
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
JP2023523790A (en) * 2020-04-30 2023-06-07 アルナイラム ファーマシューティカルズ， インコーポレイテッド COMPLEMENT FACTOR B (CFB) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
CN114057692B (en) 2020-08-07 2023-07-21 上海美悦生物科技发展有限公司 Heterocyclic compound, preparation method and application thereof
CA3188363A1 (en) 2020-08-07 2022-02-10 Linbo LUAN Complement factor b inhibitor, and pharmaceutical composition, preparation method and use thereof
AU2022325715A1 (en) * 2021-07-17 2024-02-01 Sirnaomics, Inc. Products and compositions
WO2023031359A1 (en) 2021-09-02 2023-03-09 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell
TW202333749A (en) * 2021-10-29 2023-09-01 美商艾拉倫製藥股份有限公司 Complement factor b (cfb) irna compositions and methods of use thereof
WO2023129496A2 (en) * 2021-12-27 2023-07-06 Apellis Pharmaceuticals, Inc. Rnas for complement inhibition

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (en) 1984-07-19 1989-02-17 Centre Nat Rech Scient NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
DE69034150T2 (en) 1989-10-24 2005-08-25 Isis Pharmaceuticals, Inc., Carlsbad 2'-modified oligonucleotides
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
DK0455905T3 (en) 1990-05-11 1998-12-07 Microprobe Corp Dipsticks for nucleic acid hybridization assays and method for covalent immobilization of oligonucleotides
EP0538194B1 (en) 1991-10-17 1997-06-04 Novartis AG Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
FR2687679B1 (en) 1992-02-05 1994-10-28 Centre Nat Rech Scient OLIGOTHIONUCLEOTIDES.
EP0577558A2 (en) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
JPH08504559A (en) 1992-12-14 1996-05-14 ハネウエル・インコーポレーテッド Motor system with individually controlled redundant windings
CA2159631A1 (en) 1993-03-30 1994-10-13 Sanofi Acyclic nucleoside analogs and oligonucleotide sequences containing them
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (en) 1997-03-07 2006-03-15 武 今西 Novel bicyclonucleosides and oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
NZ503765A (en) 1997-09-12 2002-04-26 Exiqon As Bi-cyclic and tri-cyclic nucleotide analogues
US6043352A (en) 1998-08-07 2000-03-28 Isis Pharmaceuticals, Inc. 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
AU1705100A (en) * 1998-10-09 2000-05-01 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
KR20070118315A (en) 1999-04-21 2007-12-14 와이어쓰 Compositions for inhibiting the function of polynucleotide sequences
JP2002543214A (en) 1999-05-04 2002-12-17 エクシコン エ／エス L-ribo-LNA analog
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
AU2698301A (en) 1999-12-30 2001-07-16 K.U. Leuven Research And Development Cyclohexene nucleic acids
US20040209276A1 (en) * 2002-09-13 2004-10-21 Smith Michael D. Thermostable reverse transcriptases and uses thereof
CA2452458A1 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US6964950B2 (en) * 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
EP1560840B1 (en) 2002-11-05 2015-05-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US6673661B1 (en) 2002-12-20 2004-01-06 Taiwan Semiconductor Manufacturing Co., Ltd. Self-aligned method for forming dual gate thin film transistor (TFT) device
US20070123466A1 (en) * 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages
ATE555118T1 (en) 2003-08-28 2012-05-15 Takeshi Imanishi NEW SYNTHETIC NUCLEIC ACIDS OF THE CROSS-LINKED N-O BOND TYPE
CA2538252C (en) 2003-09-18 2014-02-25 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
US7959919B2 (en) * 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
JP5137053B2 (en) * 2004-02-10 2013-02-06 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト Anti-factor B antibody or antigen-binding fragment thereof, composition containing the same, antigen-binding polypeptide, and therapeutic agent
EP1752536A4 (en) * 2004-05-11 2008-04-16 Alphagen Co Ltd Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
JP2008501694A (en) 2004-06-03 2008-01-24 アイシス ファーマシューティカルズ、インク． Double-stranded composition having individually modified strands for use in gene regulation
JP2008513507A (en) 2004-09-17 2008-05-01 アイシス ファーマシューティカルズ インコーポレイティッド Enhanced antisense oligonucleotides
WO2006047842A2 (en) 2004-11-08 2006-05-11 K.U. Leuven Research And Development Modified nucleosides for rna interference
GB0521716D0 (en) * 2005-10-25 2005-11-30 Genomica Sau Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
CA2640171C (en) 2006-01-27 2014-10-28 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
WO2007134181A2 (en) 2006-05-11 2007-11-22 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
CA2663601C (en) * 2006-09-22 2014-11-25 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by rna interference
CN101589143A (en) * 2006-11-27 2009-11-25 Isis药物公司 Methods for treating hypercholesterolemia
EP2125852B1 (en) 2007-02-15 2016-04-06 Ionis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
KR20090122465A (en) * 2007-03-01 2009-11-30 어드벤스드 비젼 테라피스, 인코포레이티드 Treatment of diseases characterized by inflammation
US8278425B2 (en) 2007-05-30 2012-10-02 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
CA2692579C (en) 2007-07-05 2016-05-03 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
CN103740713A (en) * 2008-07-10 2014-04-23 阿姆斯特丹大学附属医院 Complement antagonists and uses thereof
US8604192B2 (en) 2008-09-24 2013-12-10 Isis Pharmaceuticals, Inc. Cyclohexenyl nucleic acids analogs
JP6005628B2 (en) 2010-04-28 2016-10-12 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Modified nucleosides, analogs thereof, and oligomeric compounds prepared therefrom
EP2595664B1 (en) * 2010-07-19 2018-10-17 Ionis Pharmaceuticals, Inc. Modulation of nuclear-retained rna
US8658783B2 (en) * 2011-04-13 2014-02-25 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
CA2921842A1 (en) 2013-09-13 2015-03-19 Ionis Pharmaceuticals, Inc. Modulators of complement factor b
RU2701645C2 (en) * 2014-05-01 2019-09-30 Ионис Фармасьютикалз, Инк. Compositions and methods for modulating complement factor expression b

Also Published As

Publication number Publication date
CA2921842A1 (en) 2015-03-19
JP2020036600A (en) 2020-03-12
CN112359042A (en) 2021-02-12
US11926830B2 (en) 2024-03-12
RS59252B1 (en) 2019-10-31
UA119046C2 (en) 2019-04-25
AU2014318580B2 (en) 2019-12-12
ZA201601236B (en) 2017-05-31
MA38959A1 (en) 2017-08-31
MX2016003263A (en) 2016-12-08
JP6666250B2 (en) 2020-03-13
DOP2016000063A (en) 2016-06-01
EP3043827A2 (en) 2016-07-20
PE20160500A1 (en) 2016-05-21
CN105744959B (en) 2020-12-01
US20220243209A1 (en) 2022-08-04
ES2745758T3 (en) 2020-03-03
SG11201601445XA (en) 2016-03-30
DK3043827T3 (en) 2019-08-26
CL2016000606A1 (en) 2017-02-17
WO2015038939A3 (en) 2015-07-02
SG10201806787VA (en) 2018-09-27
MX371518B (en) 2020-01-31
SI3043827T1 (en) 2019-08-30
US20190048351A1 (en) 2019-02-14
JP7297112B2 (en) 2023-06-23
CL2018002334A1 (en) 2018-12-14
KR20160054595A (en) 2016-05-16
WO2015038939A2 (en) 2015-03-19
JP2016533765A (en) 2016-11-04
AU2014318580A1 (en) 2016-03-03
CN105744959A (en) 2016-07-06
RU2016113763A (en) 2017-10-16
US20200149047A1 (en) 2020-05-14
US20160222389A1 (en) 2016-08-04
EP3603677A1 (en) 2020-02-05
IL244095A0 (en) 2016-04-21
BR112016004671B1 (en) 2020-12-29
LT3043827T (en) 2019-08-12
EP3043827B1 (en) 2019-07-03
EA035433B1 (en) 2020-06-15
PH12016500443A1 (en) 2016-05-16
MY181251A (en) 2020-12-21
PT3043827T (en) 2019-09-26
AU2020201763A1 (en) 2020-04-02
HRP20191600T1 (en) 2019-11-29
JP7158363B2 (en) 2022-10-21
PL3043827T3 (en) 2020-03-31
JP2022058784A (en) 2022-04-12
EP3043827A4 (en) 2017-05-24
EA201690582A1 (en) 2016-07-29
HUE045109T2 (en) 2019-12-30
RU2662967C2 (en) 2018-07-31
PE20190354A1 (en) 2019-03-07
KR102381790B1 (en) 2022-03-31
CR20160170A (en) 2016-07-15
MX2020001258A (en) 2020-03-20

Similar Documents

Publication Publication Date Title
HK1225638A1 (en) Modulators of complement factor b
HRP20182004T1 (en) Tetrahydropyridopyrazines modulators of gpr6
HRP20171168T1 (en) P2x7 modulators
HK1254111A1 (en) P2x7 modulators
HK1218652A1 (en) P2x7 modulators p2x7
HK1218651A1 (en) P2x7 modulators p2x7
EP2968296A4 (en) Gamma-secretase modulators
SG11201604839XA (en) Wnt pathway modulators
TWI560487B (en) Electro-optical modulator
GB201321601D0 (en) Modulator
GB201312727D0 (en) Modulators
GB201318298D0 (en) Modulators
GB201317988D0 (en) Modulators
GB201304473D0 (en) Modulators
GB201306008D0 (en) Modulators of miRNA-184 mediated pathways
GB201314051D0 (en) Novel DRAK modulators